1454597-29-5

Upstream product

• 374552-25-7 C₂₄H₁₈NO₂⁽¹⁺⁾*Br^(1-) 
• 613-54-7 2-Bromo-2'-acetonaphthone 
• 14548-46-0 4-Benzoylpyridine 
• 374679-27-3 ethyl 3-(2-naphthoyl)-7-benzoylindolizine-1-carboxylate 

Downstream Products

• 1444617-19-9 C₃₄H₂₄N₂O₃ 
• 1444617-21-3 3-(2-naphthoyl)-N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-7-benzoylindolizine-1-carboxamide 
• 1454592-14-3 C₅₃H₅₅F₃N₆O₁₁ 
• 1444617-10-0 3-(2-naphthoyl)-7-benzoyl-N-ethylindolizine-1-carboxamide 
• 1444617-18-8 C₃₀H₂₂N₂O₅ 
• 1444617-11-1 C₃₀H₂₂N₂O₃ 
• 1444617-12-2 C₂₉H₂₁NO₅ 

Relevant academic research and scientific papers

Indolizine derivatives as HIV-1 VIF-elonginc interaction inhibitors

Compound 1 (VEC-5) was identified as a potent small-molecular HIV-1 viron infectivity factor inhibitor that targets the viron infectivity factor-ElonginC interaction. A structure-activity relationship study was carried out to develop compounds with improved efficacy against HIV-1 and 49 indolizine derivatives of three categories were designed and synthesized. We found that five compounds exhibited promising anti-HIV-1 activity, and the most active compound 2g had an IC50 value of 11.0 μm. These results provide new information to develop highly potent small-molecule HIV-1 viron infectivity factor inhibitors.